Defendant Favorable
12 defendant favorable decisions from Trademark Tribunal.
Defendant Favorable Decisions
12 cases | Page 1 of 1
B.M. Birla Heart Research Centre v.Shree Rajmoti Industries
The dispute concerned a proposed opposition to a trade mark application (Application No. 1279800). The question before the Tribunal was whether the notice of opposition filed by Shree Rajmoti Industries on August 28, 2006, was within the prescribed statutory period, considering procedural delays and late receipt of Trade Marks Journals.
Merck Kga A. v.Alpharma Inc.
The case involved an opposition filed by Alpharma Inc. against Merck Kga A.'s trade mark application for 'ALPHAPHARM'. The core issue was whether the notice of opposition, filed after the prescribed extension period, was still valid given procedural delays in receiving the Trade Marks Journal.
Bentec Electricals And Electronics v.Bentex Control And Switchgear Co.
The dispute concerned an opposition filed by Bentex Control & Switchgear Co. against a trademark application for 'BENTEC'. The core issue was whether the notice of opposition and the request for extension were within the statutory time limits, given delays in receiving the Trade Marks Journal.
Brooke Bond India Ltd. v.Girnar Exports (and others trading as M/s. Girnar Exports)
The dispute concerned an opposition filed by Girnar Exports against the trademark 'RED LABEL' owned by Brooke Bond India Ltd. The core issue was whether the late filing of the opposition, necessitated by a perceived error in the re-advertisement of the mark, was within the statutory period.
Amanat Tobacco Gul Manufacture v.Aftab Tobacco Products
The matter involved a Review Petition filed by Amanat Tobacco Gul Manufacture against an order that abandoned Opposition No. DEL-T-3769 regarding the registration of the trade mark 'Raja Gul Label' sought by Aftab Tobacco Products. The petitioners argued that their evidence was not considered and procedural lapses occurred, but the Tribunal found no error apparent on the face of the record.
Gujarat Medicraft Pvt. Ltd. v.Cipla Ltd.
The case involved an Interlocutory Petition filed by Cipla Ltd. (opponent) seeking permission to take evidence on record after significant delays in the trademark opposition proceedings against Gujarat Medicraft Pvt. Ltd. The Tribunal dismissed the petition, holding that procedural rules must be followed and that the opponent's failure to act within prescribed time limits constituted abandonment of the opposition.
Novartis Ag v.Natco Pharma Ltd.
Natco Pharma Ltd. opposed the patent application filed by Novartis Ag for a specific crystalline form of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not meet the criteria for enhanced efficacy under Section 3(d). Consequently, the application was refused.
Novartis Ag v.Cipla Ltd.
Cipla Ltd. opposed Novartis Ag's patent application for the ß-crystal form of imatinib mesylate. The Tribunal found that the invention was merely a new form of a known substance and did not demonstrate significant enhancement in efficacy as required under Section 3(d). Furthermore, the application was disqualified for wrongly claiming priority.
Novartis Ag v.Ranbaxy Laboratories Ltd.
Ranbaxy Laboratories Ltd., on behalf of Lakshmi Kumaran & Sridharan, opposed Novartis AG's patent application for a specific crystalline form (ß-crystal) of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not demonstrate enhanced efficacy as required under Section 3(d), leading to the refusal of the patent.
Novartis Ag v.Cancer Patients Aid Association.
The opposition was filed against Novartis AG's patent application for a specific crystalline form (ß-crystal) of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not meet the enhanced efficacy requirement under Section 3(d), leading to the refusal of the patent application.
Novartis Ag v.Hetero Drugs Limited
Novartis AG applied for a patent on the ß-crystal form of imatinib mesylate. Hetero Drugs Limited opposed the application, arguing that the invention was anticipated by prior art and did not meet the enhanced efficacy criteria under Section 3(d) of the Patents Act, 1970. The Tribunal agreed with the opposition, finding that the subject matter was a new form of a known substance without significant improvement in efficacy.
Raptakos Brett & Co. Ltd. v.Cadila Laboratories Ltd.
Raptakos Brett & Co. Ltd. opposed the trademark application for NEOPLATIN by Cadila Laboratories Ltd., arguing that it was phonetically, visually, and structurally similar to their registered mark NEOPEPTINE. The Tribunal found an apparent conflict between the marks based on overall impression and sustained the opposition.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.